Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS)

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Ultragenyx Pharmaceutical
1 program
1
BurosumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT03993821Unknown1Est. Mar 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Ultragenyx PharmaceuticalBurosumab

Clinical Trials (1)

Total enrollment: 1 patients across 1 trials

NCT03993821Ultragenyx PharmaceuticalBurosumab

Burosumab for CSHS

Start: Jul 2019Est. completion: Mar 20231 patients
Phase 1Unknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space